- Key Takeaways
- Why Pharma Is Particularly Exposed
- Identify Where the Knowledge Actually Sits
- Transfer Knowledge, Not Just Titles
- Build Internal Depth Early
- What This Looks Like in Practice
- The Mistake Employers Keep Making
- Where Pharma Succession Risk Concentrates
- The Bottom Line
- Related Reading
- Frequently Asked Questions
Drawing on our executive search practice, we put this together to give employers a grounded, practical view they can act on. Many pharmaceutical organisations face a concentration of senior expertise in leaders approaching retirement, particularly in regulatory, quality, manufacturing, and medical functions where depth takes decades to build. The risk is not simply that people will leave, but that specific, hard-won institutional and technical knowledge leaves with them, and pharmaceutical companies are unusually exposed to this.
Key Takeaways
- Deep pharma expertise takes decades and concentrates in senior people.
- Regulatory, quality, and medical knowledge is often poorly documented.
- External replacement is slow because the qualified pool is small.
- Deliberate knowledge transfer matters as much as identifying successors.
- Start succession work years before expected departures.
Why Pharma Is Particularly Exposed
Pharmaceutical expertise, understanding a product’s regulatory history, why a process was validated a particular way, what commitments were made to which agency, how a safety question was resolved a decade ago, accumulates over long careers and is frequently held in people’s heads rather than in accessible records. When those people retire, the company loses not just capability but memory. Because the pool of externally available replacements with comparable depth is small, and because much of the lost knowledge is company-specific rather than generic, this exposure is greater in pharmaceutical companies than in many other sectors.
Identify Where the Knowledge Actually Sits
Effective succession work starts with an honest map of where critical knowledge is concentrated, which is often not the same as the organisational chart. A regulatory director who has managed a product’s dossier for fifteen years may hold more consequential knowledge than their VP. Identify the individuals whose departure would create real difficulty, in regulatory, quality, manufacturing, medical, and technical roles, and treat those as the succession priority regardless of title. This mapping exercise frequently surprises leadership teams and is worth doing explicitly.
Transfer Knowledge, Not Just Titles
Naming a successor does not transfer knowledge. What works is deliberate overlap and documentation: pairing successors with incumbents on live work, having incumbents document regulatory histories, process rationales, and agency commitments, and creating time for the questions that only arise when handling real situations. This takes months or years and requires the incumbent’s genuine cooperation, which is easier to secure when the transition is planned and respectful rather than sudden. Companies that leave this until a retirement notice arrives lose most of what was transferable.
Build Internal Depth Early
Given the slowness of external replacement, the reliable answer is internal development started well in advance: giving high-potential people in critical technical functions broader exposure, rotating them across products and issues, and letting them handle consequential work with support. This takes years, which is precisely why it must begin before the need is visible. Companies that wait until a retirement is announced are choosing between an unprepared internal candidate and a lengthy external search, both of which carry more risk than the development they did not do.
What This Looks Like in Practice
A pharmaceutical company maps where critical technical and institutional knowledge actually sits rather than assuming it follows the organisational chart, begins internal development in those areas years ahead, and structures deliberate overlap and documentation so that knowledge transfers rather than only titles, securing incumbent cooperation through planned and respectful transitions.
The Mistake Employers Keep Making
The most common mistake is treating succession as a matter of identifying replacements when retirements are announced, which addresses the org chart while losing the knowledge. The named successor holds the title but not the fifteen years of context about why the process was validated that way or what was committed to which agency, and the company discovers the gap during the next inspection or regulatory question.
Where Pharma Succession Risk Concentrates
| Function | Knowledge at Risk |
|---|---|
| Regulatory | Product dossier history and agency commitments |
| Quality | Rationale behind validated processes and past findings |
| Manufacturing | Process knowledge and deviation history |
| Medical and safety | Historical signal evaluations and their basis |
| Technical specialists | Company-specific expertise with no external equivalent |
The Bottom Line
Pharmaceutical companies are unusually exposed to knowledge loss through senior retirement because critical regulatory, quality, and technical understanding accumulates over decades and is often undocumented, so map where it sits, begin internal development years ahead, and structure deliberate overlap so knowledge transfers rather than only titles. Get this right and the hire becomes a genuine multiplier; get it wrong and no amount of general talent compensates.
Related Reading
For more, see Hiring Trends in Pharmaceutical Manufacturing Leadership, Hiring a VP of Regulatory Affairs for Global Pharma Companies, How to Hire a Head of Pharmacovigilance.
Frequently Asked Questions
- Q: Why is pharma particularly exposed to retirement risk?
- A: Because critical expertise, regulatory histories, validation rationales, agency commitments, accumulates over long careers, is often undocumented, and is company-specific rather than externally replaceable.
- Q: Where should succession planning focus?
- A: On individuals whose departure would create genuine difficulty, which frequently means senior technical specialists rather than only the most senior titles.
- Q: How do you transfer this kind of knowledge?
- A: Through deliberate overlap on live work, documentation of regulatory histories and process rationales, and time for questions that arise only when handling real situations.
- Q: Why must internal development start early?
- A: Because building comparable depth takes years and external replacement is slow, so waiting until a retirement is announced leaves only poor options.
- Q: What does naming a successor accomplish?
- A: Continuity of the role, but not of the knowledge, which requires deliberate transfer over months or years with the incumbent’s genuine cooperation.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
